Findings

What do systematic reviews say?

97 questions · 98 findings · 53 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 13 · 13.3%GRADE not reported 1 · 1%Very low 17 · 17.3%Low 34 · 34.7%Moderate 20 · 20.4%High 13 · 13.3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Reslizumab intravenous (IV) vs placebo · Health‐related quality of life (ACQ)Scale from: 0 to 6 (lower is better)
  Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1652 participants
  High
Direct match · question page
- Mepolizumab subcutaneous (SC) vs placebo · Health‐related quality of life (SGRQ)Scale from: 0‐100 (lower is better)
  Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1231 participants
  High
Direct match · question page
- Mepolizumab subcutaneous (SC) vs placebo · Health‐related quality of life (ACQ)Scale from: 0‐6 (lower is better)
  Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 1231 participants
  High
Direct match · question page
- C1 esterase inhibitor vs placebo or active control · Quality of lifestandardised mean difference (lower is better) (during
  Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low
Direct match · question page
- Benralizumab subcutaneous (SC) vs placebo · Health‐related quality of life (ACQ)Scale from: 0‐6 (lower is better)
  Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2791 participants
  High

Early enteral nutrition within 24 hours of lower gastrointestinal surgery vs later commencement

Quality of life · lower gastrointestinal surgery

1 finding from 1 review

Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

Lipid‐lowering agent vs placebo or no treatment

Quality of life · asymptomatic carotid stenosis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Lowered blood pressure vs placebo

Quality of life · people with acute subarachnoid haemorrhage

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for altering blood pressure in people with acute subarachnoid haemorrhage 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sertraline vs cognitive behavioural therapy

Quality of life (QOLIE‐89) (1‐ to 3‐month periods) · people with epilepsy and depression

1 finding from 1 review

Antidepressants for people with epilepsy and depression 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Moderate

Brief psychotherapeutic intervention vs usual care

Quality of life As assessed by SF‐36 (lower is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Psychotherapy preceded by motivational interviewing vs psychotherapy alone

Quality of life As measured by QOLIE10 (lower is better) · people with conversion disorder according to DSM‐IV or ICD‐10 criteria

1 finding from 1 review

Psychosocial interventions for conversion and dissociative disorders in adults 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Exercise vs no treatment

QoL · people with non‐ulcerated chronic venous insufficiency

It is very uncertain whether physical exercise changes quality of life VEINES‐QOL/SF‐36/CIVIQ‐20 (lower is better) compared with no treatment (very low certainty).

1 finding from 1 review

Physical exercise for the treatment of non‐ulcerated chronic venous insufficiency 2023 · Cochrane Headline outcomes only
MD 4.6
2 studies · 61 participants
Very low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Balneotherapy vs no treatment

Health‐related quality of life –CIVIQ2 Scale: 20–100 · people with chronic venous insufficiency

1 finding from 1 review

Balneotherapy for chronic venous insufficiency 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 153 participants
Very low

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Mepolizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Benralizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2791 participants
High

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Intervention vs usual care

Quality of life ‐ CAT · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Low

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Reslizumab subcutaneous (SC) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High

Mepolizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1231 participants
High

Intervention vs usual care

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · COPD and at least one other long‐term condition

1 finding from 1 review

Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Low

Reslizumab subcutaneous (SC) vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 464 participants
High